Navigation Links
Spine patients who quit smoking report diminished pain
Date:3/18/2013

CHICAGO Smoking is a known risk factor for back pain and disc disease. In a new study presented today at the 2013 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS), researchers reviewed smoking cessation rates and related pain in 6,779 patients undergoing treatment for spinal disorders with severe axial (spine) or radicular (leg) pain. Information on each patient's age, gender, weight, smoking history, assessment of pain, treatment type and co-morbid depression also were assessed.

Overall, 8.9 percent of patients over the age of 55 smoked compared with 23.9 percent of those aged 55 and younger. Twenty-five percent of the patients older than age 55 had quit smoking, as did 26.1 percent of those younger than age 55.

Current smokers in both age groups reported greater pain than those who had never smoked. Mean improvement in reported pain over the course of treatment was significantly different in non-smokers and current smokers in both age groups.

Those who quit smoking during the course of care reported greater pain improvement than those who continued to smoke. As a group, those who continued smoking during treatment had no clinically significant improvement in reported pain, regardless of age.


'/>"/>

Contact: Lauren Pearson Riley
pearson@aaos.org
708-227-1773
American Academy of Orthopaedic Surgeons
Source:Eurekalert

Page: 1

Related biology news :

1. Human-like spine morphology found in aquatic eel fossil
2. Renewal grant supports genetic research into arthritis of the spine
3. Researchers in Manchester find genetic key to preventing spine tumors
4. Spinal tap -- using cactus spines to isolate DNA
5. Reproductive health providers should discuss environmental exposure risks with patients
6. Low-calorie diet may be harmful for bowel disease patients
7. Interventional radiology: Mitigating symptoms, improving quality of life of MS patients
8. Interventional radiologists see significant symptom relief in MS patients
9. Crestor Delivers Latest LDL-C Targets in High-Risk Patients at Lower Doses than Other Statins
10. Tokai Pharmaceuticals galeterone well-tolerated in patients with advanced prostate cancer
11. Obese patients face higher radiation exposure from CT scans -- but new technology can help
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
(Date:3/22/2016)... PROVO and SANDY, ... Screening Ontario (NSO), which operates the highest sample volume ... testing, and Tute Genomics and UNIConnect, leaders in clinical ... today announced the launch of a project to establish ... testing panel. NSO has been contracted ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
Breaking Biology Technology: